Terns Pharmaceuticals (TERN) Peer Comparison
$52.95
$52.15
(6,518.75%)
As on 15-May-2026 16:00EDT
Market cap
$6,117 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.1
Div. Yield
0 %
Edit
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
Market cap ($ Mln) |
6,117 | 6,732 | 1,728 | 251 |
Revenue ($ Mln) |
-- | 22 | -- | 5 |
Net Profit ($ Mln) |
-96.21 | -228.93 | -235.09 | 11.99 |
Net Margin (%) |
-- | -1,027.25 | -- | -87.52 |
RoE (%) |
-14.23 | -53.42 | -90.96 | 162.49 |
Price to Earnings |
-- | -- | -- | 137.50 |
Price-To-Book |
6.08 | 16.73 | 163.79 | 0.00 |
Income Statement ($ Mln)
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 22.29 | 0.00 | 30.20 |
|
Cost of Revenue
|
-- | 6.68 | 0.03 | 3.02 |
|
Gross Profit
|
-- | 15.61 | -0.03 | 27.18 |
|
Operating Expenses
|
110.12 | 268.69 | 210.87 | 3.15 |
|
Operating Profit (EBIT)
|
-110.12 | -253.08 | -210.87 | 24.03 |
|
Other Income
|
-- | -- | -- | -- |
|
Profit before Tax
|
-95.63 | -228.87 | -209.79 | 24.43 |
|
Provision for Tax
|
0.58 | 0.07 | 0.05 | -0.81 |
|
Profit after Tax (Net Income)
|
-96.21 | -228.93 | -209.84 | 23.62 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- |
Liabilities ($ Mln)
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
1,006.52 | 402.35 | 240.38 | 31.86 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
2.14 | 97.44 | 0.08 | 1.65 |
|
Current Liabilities
|
16.41 | 104.20 | 20.07 | 4.55 |
|
Total Liabilities
|
1,025.08 | 603.99 | 260.53 | 38.06 |
Assets ($ Mln)
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Non-Current Assets
|
0.88 | 141.81 | 0.10 | 37.07 |
|
Current Assets
|
1,024.19 | 462.18 | 260.42 | 0.99 |
|
Total Assets
|
1,025.08 | 603.99 | 260.53 | 38.06 |
|
Total Debt*
|
0.92 | 96.26 | 0.07 | 1.85 |
|
Net Current Assets
|
1,007.78 | 357.98 | 240.36 | -- |
Cashflow ($ Mln)
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-82.18 | -210.26 | -6.73 | -1.18 |
|
Cash Flow from Investing Activities
|
-298.04 | 86.30 | -17.37 | -0.05 |
|
Cash from Financing Activities
|
743.51 | 98.53 | 266.84 | 0.50 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
ROCE (%)
|
-14.20 | -45.45 | -163.71 | 114.98 |
|
ROE (%)
|
-14.23 | -53.42 | -163.80 | 120.40 |
|
ROA (%)
|
-13.85 | -34.81 | -151.15 | 98.59 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-- | -1,027.25 | -- | 78.21 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -0.79 | -- | 4.81 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-8.28 | -113.26 | -878.77 | 96.95 |
|
EPS Growth (%)
|
-0.06 | -1.03 | -6.09 | 0.97 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Price / Earnings
|
-39.12 | -16.04 | -0.18 | -- |
|
Price / Book Value
|
3.74 | 9.12 | 0.15 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-24.93 | -16.76 | 1.05 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.24 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
0.00 | 0.02 | 0.00 | 0.01 |
|
Current Ratio
|
62.41 | 4.44 | 12.98 | 0.22 |
|
Quick Ratio
|
-- | -- | -- | -- |
|
Interest Coverage
|
-- | -8.45 | -- | 0.00 |
Operating Efficiency Ratios
| Terns Pharmaceuticals (TERN) | Arcellx Inc (ACLX) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 16.15 | -- | 0.82 |
|
Asset Turnover
|
0.00 | 0.03 | 0.00 | 1.26 |
|
Receivable days
|
-- | 59.00 | -- | 1.68 |
|
Inventory Days
|
-- | -- | -- | -- |
|
Payable days
|
-- | 209.78 | 4,409.86 | 80.25 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
